MedTrace Logo

Hyperimmune Plasma for Critical Patients With COVID-19

NCT04321421 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2020-05-28

No results posted yet for this study

Summary

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become pandemic. To date, no specific treatment has been proven to be effective. Promising results were obtained in China using Hyperimmune plasma from patients recovered from the disease.The investigators plan to treat critical Covid-19 patients with hyperimmune plasma.

Conditions

Interventions

OTHER

hyperimmune plasma

administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5

Sponsors & Collaborators

  • OSPEDALE CARLO POMA ASST MANTOVA

    collaborator UNKNOWN

  • Fondazione IRCCS Policlinico San Matteo di Pavia

    lead OTHER

Principal Investigators

  • Cesare Perotti, MD · Fondazione IRCCS Policlinico San Matteo di Pavia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-17
Primary Completion
2020-04-28
Completion
2020-05-07

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04321421 on ClinicalTrials.gov